title: Overview of fluoroquinolone safety.
abstract: The safety of the fluoroquinolone antimicrobial agents is reviewed, discussing documented and potential clinical and laboratory adverse effects and drug-drug interactions. In prospective, randomized, double-blind clinical trials comparing fluoroquinolones to nonquinolone drugs or placebo, the fluoroquinolones were not significantly different (22 studies) or were superior (5 studies) to comparison agents but were only rarely more toxic (2 studies). Adverse effects included mild gastrointestinal toxicities and less common but more problematic central nervous system toxicities. Clinically important interactions occurred with coadministration of antacids and all fluoroquinolones and with theophylline and enoxacin and to a lesser extent ciprofloxacin and pefloxacin but not other fluoroquinolones. Potential adverse effects such as cartilage damage, DNA damage, teratogenicity, and crystalluria, while of concern, have not as yet been shown to be of clinical importance. Therapy of bacterial infections in children and adolescents is relatively contraindicated, but growing clinical experience with treatment of these patients has not so far revealed serious bone or cartilage toxicity. The fluoroquinolones thus far have exhibited a favorable safety profile, but our clinical experience is still limited, and monitoring for as yet unappreciated toxicities is warranted.
authors.affiliation: Infectious Disease Unit, Massachusetts General Hospital, Boston 02114-2696.
authors.forename: J S
authors.initials: JS
authors.lastname: Wolfson
authors.forename: D C
authors.initials: DC
authors.lastname: Hooper
mesh_terms: D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000009:adverse effects*; D004347:Drug Interactions; D006801:Humans
chemical_list: D042462:4-Quinolones; D000890:Anti-Infective Agents